权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Center for Pre-Clinical Cancer Research

临床前癌症研究中心

基本信息

批准号：
10360591
负责人：
JOSEPH FRANCIS
金额：
$ 210.6万
依托单位：
LOUISIANA STATE UNIV A&M COL BATON ROUGE
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-03-01 至 2026-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10360591
关键词：
3-Dimensional Address Affect African American population Animal Diseases Animal Model Antineoplastic Agents Award Biomedical Research Cancer Model Cell Culture System Centers of Research Excellence Clinical Trials Communities Complement Core Facility Culture Techniques Development Disease Disease model Doctor of Philosophy Equipment Evaluation Exhibits Extramural Activities Funding Goals Heterogeneity Historically Black Colleges and Universities Human In Vitro Individual Infectious Diseases Research Infrastructure Louisiana Lung Malignant Neoplasms Malignant neoplasm of liver Malignant neoplasm of prostate Mentored Research Scientist Development Award Mentorship Mission Modeling Molecular Biology Mus NCI Center for Cancer Research Outcome Patients Phase Phenotype Pre-Clinical Model Research Research Personnel Research Project Grants Resources Role System Technology Therapeutic Training United States National Institutes of Health Universities Veterinary Medicine Veterinary Schools anticancer research clinically relevant disease phenotype experience health disparity human disease immunopathology in vivo in vivo Model insight malignant breast neoplasm mortality mouse model neoplastic cell novel therapeutic intervention novel therapeutics osteosarcoma pre-clinical preclinical evaluation programs success therapy outcome three dimensional cell culture three-dimensional modeling translational approach translational therapeutics tumor tumor microenvironment tumor progression tumorigenesis

项目摘要

Summary Overall Core. The Center for Pre-Clinical Cancer Research (Cancer COBRE) aims to identify clinically relevant mechanisms of human cancer disease using models that closely reflect the disease state in the context of the tumor microenvironment. Recent advances in 3D tumor culture techniques have intensified the focus on in vitro human cell culture systems to reveal insights into human tumorigenesis and thus drive novel therapeutic discovery. Promising Junior Investigators (PJIs) address devastating human cancer diseases that exhibit poor outcomes in patients and for which there are unmet therapeutic needs. The four PJI projects feature osteosarcoma, breast cancer, liver cancer, and prostate cancer as diseases that would benefit from pre-clinical models that are more predictive of mechanistic efficacy in humans. All of the PJI projects will use specialized in vivo mouse models and/or in vitro 3D tumor spheroids to identify relevant mechanisms of tumorigenesis or for evaluation of novel therapeutic strategies. The Center will promote a unified and coordinated approach by establishing a new specialized core facility, Pre- Clinical Evaluation Core (PCEC), to provide scientific expertise and technical support for the pre-clinical evaluation of the PJI projects. The unique PCEC will provide a centralized approach that will support exploratory and translational assessment of cancer disease mechanisms and therapeutic strategies in humans. To accomplish this approach, advanced 3D cell culture systems will provide critical translational information. and bridge the gap between animal models and human therapeutic outcomes. The new Molecular Biology and Immunopatholgy Core (MBIPC) will provide access to state-of-the-art equipment and expertise in Molecular Biology and Immunopathology while leveraging extensive resources at LSU SVM. Human and animal diseases are a major focus at the LSU SVM and on the LSU campus. The Center has three Aims: Aim 1. To create a Center for Pre-Clinical Cancer Research to promote and support centralized management and coordination of pre-clinical evaluation of tumorigenesis mechanisms and translational therapeutic approaches. Aim 2. To provide the COBRE PJIs and other investigators with a core infrastructure for resources and support for advanced pre-clinical cancer disease research that will enhance PJI individual competitiveness for extramural funding. Aim 3. To provide training and mentorship on pre-clinical evaluation using state-of-the-art in vitro 3D tumor spheroids to complement in vivo cance disease modeling.

整体核心。临床前癌症研究中心（癌症COBRE）旨在临床上识别使用密切反映疾病的模型研究人类癌症疾病的相关机制在肿瘤微环境的背景下。肿瘤三维培养的研究进展技术已经加强了对体外人类细胞培养系统的关注，深入了解人类肿瘤发生，从而推动新的治疗发现。有前途的初级研究人员（PJIs）解决毁灭性的人类癌症疾病这些疾病在患者中表现出不良结局，需求这四个PJI项目的特点是骨肉瘤，乳腺癌，肝癌，前列腺癌作为疾病，将受益于临床前模型，预测人体的机械功效。所有的PJI项目都将使用专门的体内小鼠模型和/或体外3D肿瘤球体，以确定相关机制或用于评价新的治疗策略。中心将促进建立一个新的专门核心基金，临床评价核心（PCEC），为 PJI项目的临床前评价。独特的PCEC将提供一个集中的支持癌症疾病探索性和转化性评估的方法机制和治疗策略。为了实现这种方法，高级 3D细胞培养系统将提供关键的翻译信息。弥合差距动物模型和人类治疗结果之间的关系。新的分子生物学和免疫病理学核心（MBIPC）将提供最先进的设备，分子生物学和免疫病理学的专业知识，同时利用广泛的资源， LSU SVM。人类和动物疾病是LSU SVM和LSU的主要焦点校园该中心有三个目标：目标1。创建临床前癌症中心研究如何促进和支持集中管理和协调肿瘤发生机制和转化治疗的临床前评价接近。目标二。为COBRE PJI和其他调查人员提供核心为晚期临床前癌症疾病提供资源和支持的基础设施研究，这将提高PJI个人竞争力的校外资金。目的 3.使用最新技术提供临床前评价培训和指导，体外3D肿瘤球体可补充体内癌症疾病建模。